Islamic Countries Acknowledge Importance of Self-Reliance in Vaccine Production

BANDUNG, Indonesia, August 9, 2010 - Islamic countries have acknowledged the importance of self-reliance in
vaccine production and are committed to establishing closer cooperation
towards achieving it, as they ended their 6th Annual Meeting of Self-Reliance
in Vaccine Production (SRVP), in Bandung, Indonesia.

SRVP is supported by Islamic Development Bank (IDB), whereas the
three-day meeting that was finalized on Monday (9/8) has elected Biofarma as
the new focal point for Projects Implementation Monitoring and Razi Institute
of Iran as the Training Manager; each of these institutions should provide
the IDB with the name and contact address of their respective staff member in
charge of this responsibility.

The participants have also discussed the serious negative effects of
current sanctions against Islamic Republic of Iran on the development and
production of vaccines, which are essential to the health of the populations.

Considering the increasing constraints caused by ever more stringent
requirements from the WHO, the SRVP members agreed to constitute a task force
from within their membership to formulate their proposals for input in the
new WHO draft prequalification guidelines. Indonesia will assist vaccine
producers in OIC countries to accelerate their achievement of WHO
prequalification.

In order to speed up the implementation of the SRVP program over the
coming year, they have proposed to constitute a resource base of relevant
experts and consultants to help supervise the implementation of approved
projects and the formulation of new proposals. To this effect, each SRVP
member has been requested to upload its information in the SRVP web portal:
Bio Farma will monitor this activity.

Considering the importance of promoting the production of halal vaccines
by the OIC vaccine producers, the IDB is requested to support the convening
of relevant consultations for a and the consultations of religious
authorities for the establishment of relevant references and guidelines for
this new industry: the monitoring team will be constituted of Bio Farma, Nine
Bio and Razi Institute.

Considering the high cost and high risk associated with the development
and production of vaccine, in particular Foot and Mouth Disease (FMD)
vaccine, the SRVP Group strongly recommends the involvement of the private
sector, in particular within Public Private Partnership and the collaboration
with Global Alliances Financiers with the support of IDB. Indonesia will open
access to OIC countries for the development of new vaccines by using its new
platform technology of delivery system.

The meeting was attended by Indonesia, Iran, Malaysia, Mali, Mozambique,
Nigeria, Pakistan, Senegal, Tunis and representatives of IDB, WHO as well as
relevant experts as guest speakers from Australia and Belgium.

    For further information, please contact:
    M. Rahman Rustan
    Corporate Secretary
    PT. Bio Farma (Persero)
    Phone: +6222-2033755
    Fax: +6222-2041306
    Website: www.biofarma.co.id

M. Rahman Rustan, Corporate Secretary, PT. Bio Farma (Persero), +6222-2033755, Fax: +6222-2041306